Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 02/29/24
Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate UpdateGlobeNewsWire • 02/15/24
Verona Pharma enters into Debt Facility of up to $400 Million with Oxford Finance and Hercules CapitalGlobeNewsWire • 01/02/24
Wall Street Analysts Believe Verona Pharma PLC American Depositary Share (VRNA) Could Rally 135.87%: Here's is How to TradeZacks Investment Research • 11/23/23
Verona Pharma's Ensifentrine: Potentially A New Era In Respiratory Disease TreatmentSeeking Alpha • 11/18/23
Verona Pharma's President and CEO David Zaccardelli Wins Executive of the Year SCRIP AwardGlobeNewsWire • 11/17/23
Does Verona Pharma PLC American Depositary Share (VRNA) Have the Potential to Rally 119.18% as Wall Street Analysts Expect?Zacks Investment Research • 11/07/23
Verona Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/02/23
Verona Pharma to Report Third Quarter 2023 Financial Results and Provide Corporate UpdateGlobeNewsWire • 10/19/23
Verona Pharma PLC American Depositary Share (VRNA) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?Zacks Investment Research • 10/11/23
Verona Pharma to Host Investor Update on Commercialization Preparation for Ensifentrine on October 18, 2023GlobeNewsWire • 10/06/23
Down -21.27% in 4 Weeks, Here's Why Verona Pharma PLC American Depositary Share (VRNA) Looks Ripe for a TurnaroundZacks Investment Research • 10/04/23
Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at CHEST 2023GlobeNewsWire • 10/03/23
Verona Pharma Announces the US FDA has Accepted the New Drug Application Filing for Ensifentrine for the Maintenance Treatment of COPDGlobeNewsWire • 09/11/23
Verona Pharma to Present Additional Analysis of Phase 3 ENHANCE-1 Study in COPD at ERS International Congress 2023GlobeNewsWire • 09/06/23